Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MIRM NASDAQ:MLTX NASDAQ:ORIC NASDAQ:PTGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMIRMMirum Pharmaceuticals$73.87-2.2%$57.15$36.86▼$75.74$3.79B0.94930,933 shs1.08 million shsMLTXMoonLake Immunotherapeutics$55.75+1.7%$51.68$31.42▼$58.26$3.52B1.27416,945 shs607,821 shsORICOric Pharmaceuticals$10.23+2.0%$10.38$3.90▼$14.67$974.14M1.69763,636 shs711,532 shsPTGXProtagonist Therapeutics$59.05+1.6%$54.58$33.31▼$61.89$3.62B2.33657,634 shs792,267 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMIRMMirum Pharmaceuticals-2.20%+3.29%+44.50%+66.60%+68.38%MLTXMoonLake Immunotherapeutics+1.73%-0.25%+10.48%+42.73%+19.10%ORICOric Pharmaceuticals+1.99%+5.03%-4.48%+23.85%+0.59%PTGXProtagonist Therapeutics+1.57%+2.73%+8.11%+24.89%+38.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMIRMMirum Pharmaceuticals3.3071 of 5 stars2.60.00.04.23.41.70.6MLTXMoonLake Immunotherapeutics1.813 of 5 stars3.41.00.00.02.22.50.0ORICOric Pharmaceuticals4.7845 of 5 stars4.53.00.04.42.63.30.6PTGXProtagonist Therapeutics1.8839 of 5 stars2.53.00.00.03.02.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMIRMMirum Pharmaceuticals 3.13Buy$74.130.35% UpsideMLTXMoonLake Immunotherapeutics 2.78Moderate Buy$74.4333.50% UpsideORICOric Pharmaceuticals 2.90Moderate Buy$17.6372.29% UpsidePTGXProtagonist Therapeutics 3.00Buy$67.2013.80% UpsideCurrent Analyst Ratings BreakdownLatest ORIC, MIRM, MLTX, and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025ORICOric PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$20.00 ➝ $17.008/14/2025ORICOric PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $19.008/13/2025ORICOric PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.008/12/2025ORICOric PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold8/11/2025MIRMMirum PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy$89.008/8/2025MIRMMirum PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$77.00 ➝ $89.008/7/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy8/7/2025PTGXProtagonist TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform8/7/2025MIRMMirum PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetMarket Outperform ➝ Market Outperform$79.00 ➝ $81.008/7/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$77.00 ➝ $82.008/7/2025MIRMMirum PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$73.00 ➝ $80.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMIRMMirum Pharmaceuticals$336.89M11.02N/AN/A$5.08 per share14.54MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$5.57 per shareN/AORICOric PharmaceuticalsN/AN/AN/AN/A$3.34 per shareN/APTGXProtagonist Therapeutics$434.43M8.46$4.59 per share12.87$10.74 per share5.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMIRMMirum Pharmaceuticals-$87.94M-$1.21N/AN/AN/A-13.65%-24.76%-8.50%11/11/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$118.94M-$2.78N/AN/AN/AN/A-40.98%-35.81%11/6/2025 (Estimated)ORICOric Pharmaceuticals-$127.85M-$1.89N/AN/AN/AN/A-51.75%-47.09%11/11/2025 (Estimated)PTGXProtagonist Therapeutics$275.19M$0.7084.36N/AN/A24.88%8.12%7.41%11/6/2025 (Estimated)Latest ORIC, MIRM, MLTX, and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ORICOric Pharmaceuticals-$0.46-$0.47-$0.01-$0.47N/AN/A8/6/2025Q2 2025MIRMMirum Pharmaceuticals-$0.31-$0.12+$0.19-$0.12$107.91 million$127.79 million8/6/2025Q2 2025PTGXProtagonist Therapeutics-$0.53-$0.55-$0.02-$0.55$8.32 million$5.55 million8/5/2025Q2 2025MLTXMoonLake Immunotherapeutics-$0.73-$0.87-$0.14-$0.87N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMIRMMirum Pharmaceuticals1.213.132.97MLTXMoonLake Immunotherapeutics0.2116.6516.65ORICOric PharmaceuticalsN/A16.1316.13PTGXProtagonist TherapeuticsN/A16.9716.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMIRMMirum PharmaceuticalsN/AMLTXMoonLake Immunotherapeutics93.85%ORICOric Pharmaceuticals95.05%PTGXProtagonist Therapeutics98.63%Insider OwnershipCompanyInsider OwnershipMIRMMirum Pharmaceuticals14.36%MLTXMoonLake Immunotherapeutics12.02%ORICOric Pharmaceuticals6.82%PTGXProtagonist Therapeutics4.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMIRMMirum Pharmaceuticals14050.24 million43.02 millionOptionableMLTXMoonLake Immunotherapeutics264.23 million56.51 millionOptionableORICOric Pharmaceuticals8097.12 million90.50 millionOptionablePTGXProtagonist Therapeutics12062.21 million59.16 millionOptionableORIC, MIRM, MLTX, and PTGX HeadlinesRecent News About These CompaniesJump Financial LLC Acquires New Position in Protagonist Therapeutics, Inc. $PTGXAugust 29 at 5:19 AM | marketbeat.comPrice T Rowe Associates Inc. MD Sells 70,646 Shares of Protagonist Therapeutics, Inc. $PTGXAugust 29 at 4:05 AM | marketbeat.comAxiom Investors LLC DE Invests $1.93 Million in Protagonist Therapeutics, Inc. $PTGXAugust 27 at 7:02 AM | marketbeat.comNuveen LLC Buys Shares of 152,771 Protagonist Therapeutics, Inc. $PTGXAugust 27 at 3:38 AM | marketbeat.comRusfertide wins Breakthrough Therapy status from FDAAugust 27 at 2:18 AM | thepharmaletter.comTProtagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025August 26, 2025 | accessnewswire.comAWellington Management Group LLP Buys 47,293 Shares of Protagonist Therapeutics, Inc. $PTGXAugust 26, 2025 | marketbeat.comState of New Jersey Common Pension Fund D Purchases Shares of 53,736 Protagonist Therapeutics, Inc. $PTGXAugust 24, 2025 | marketbeat.comProtagonist Therapeutics, Inc. $PTGX Shares Sold by American Century Companies Inc.August 24, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Sells 20,691 Shares of Protagonist Therapeutics, Inc. $PTGXAugust 23, 2025 | marketbeat.comVanguard Group Inc. Has $206.85 Million Holdings in Protagonist Therapeutics, Inc. $PTGXAugust 22, 2025 | marketbeat.comInvesco Ltd. Has $41.57 Million Position in Protagonist Therapeutics, Inc. $PTGXAugust 20, 2025 | marketbeat.comDeutsche Bank AG Has $3.18 Million Holdings in Protagonist Therapeutics, Inc. $PTGXAugust 20, 2025 | marketbeat.comE Fund Management Co. Ltd. Sells 71,950 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)August 18, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Public Sector Pension Investment BoardAugust 15, 2025 | marketbeat.comInformed Momentum Co LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)August 13, 2025 | marketbeat.comKnott David M Jr Purchases 23,632 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)August 12, 2025 | marketbeat.comDoes Protagonist Therapeutics’ (PTGX) Widening Loss and Shelf Registration Signal a Strategic Pivot?August 12, 2025 | finance.yahoo.comWedbush Has Positive Estimate for PTGX Q3 EarningsAugust 11, 2025 | marketbeat.comWedbush Expects Higher Earnings for Protagonist TherapeuticsAugust 9, 2025 | marketbeat.com7PTGX : What 4 Analyst Ratings Have To Say About Protagonist...August 8, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesJoby Aviation: Why a Historic Flight Outweighs Analyst DowngradesBy Jeffrey Neal Johnson | August 19, 2025Mercury Systems Up 27%: Financials Send Investors a Clear SignalBy Jeffrey Neal Johnson | August 14, 2025Equal Weight ETFs: Hidden Upside in Today’s MarketBy Gabriel Osorio-Mazilli | August 23, 2025Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick?By Chris Markoch | August 28, 2025MarketBeat Week in Review – 08/18 - 08/22By MarketBeat Staff | August 23, 2025ORIC, MIRM, MLTX, and PTGX Company DescriptionsMirum Pharmaceuticals NASDAQ:MIRM$73.87 -1.66 (-2.20%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$72.93 -0.94 (-1.28%) As of 08/29/2025 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.MoonLake Immunotherapeutics NASDAQ:MLTX$55.75 +0.95 (+1.73%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$56.61 +0.86 (+1.55%) As of 08/29/2025 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Oric Pharmaceuticals NASDAQ:ORIC$10.23 +0.20 (+1.99%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$10.23 0.00 (0.00%) As of 08/29/2025 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Protagonist Therapeutics NASDAQ:PTGX$59.05 +0.91 (+1.57%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$59.96 +0.91 (+1.53%) As of 08/29/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
